Case-Control Study Finds No Association Between G6PD Deficiency and Systemic Lupus Erythematosus Risk in Females

This case-control study evaluated the association between G6PD deficiency and systemic lupus erythematosus. The study population consisted of 516 female systemic lupus erythematosus patients and 491 age-matched healthy females enrolled between August 2023 and August 2024. The primary objective was to assess G6PD deficiency rates, gene mutation rates, and mutation types to determine risk correlation specifically.

Analysis of G6PD enzymatic deficiency rates revealed 9.69% (50/516) in the systemic lupus erythematosus group and 10.79% (53/491) in the control group respectively. Gene mutation rates in enzymatic deficiency subgroups were 84.00% in the systemic lupus erythematosus group versus 88.68% in the control group. In normal enzymatic subgroups, rates were 8.37% in the systemic lupus erythematosus group versus 10.05% in the control group. All comparisons yielded P > 0.05, indicating no significant difference overall. Most common mutations, c.1376G > T and c.1388G > A, showed similar frequencies in both groups. No novel variants were identified by whole-exome sequencing.

Safety data regarding adverse events, serious adverse events, and discontinuations were not reported. The study was funded by the Yangjiang High-level Key Medical and Health Research Project (2023001). Limitations were not explicitly detailed in the provided data. Clinicians should interpret these findings cautiously, as observational designs cannot establish causality. The current data suggests G6PD deficiency does not correlate with the risk of developing systemic lupus erythematosus in this female population, but further investigation is warranted.